Criteria for the selection of nuclides for radioimmunotherapy [electronic resource].
- Cambridge, Mass. : Harvard University, 1986.
Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy.
- Physical Description:
- Pages: 9 : digital, PDF file
- Additional Creators:
- Harvard University
United States. Department of Energy. Office of Scientific and Technical Information
- This report describes many factors that need to be considered if radioimmunotherapy is to become a commonplace reality. For beta-emitting radionuclides, two physical features of importance are half-life and energy, with the latter determining the range. These features must be matched to the pharmacokinetics of the carrier and the distribution of the radionuclide, both macroscopically and microscopically. Alpha-particle emitters could be considered for cells that are readily accessible to the labeled antibody and for populations that uniformly and constantly display the targeted antigen or idiotype, e.g., trafficking cells such as T or B lymphocytes. For cells that concentrate the radioactive label, the use of low-energy electrons should be examined. If the radionuclide is translocated to the nucleus, the Auger effect can be particularly lethal because of the high LET-like biological response. 15 refs., 3 figs., 2 tabs.
- Published through SciTech Connect.
Symposium on radiolabeled monoclonal antibodies for imaging and therapy: potential, problems, and prospects, Pascoli, Italy, 20 Jul 1986.
Adelstein, S.J.; Kassis, A.I.
- Funding Information:
View MARC record | catkey: 14081838